Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer ...Middle East

– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy – – If approved, PADCEV with KEYTRUDA would be the first combination in Japan to offer an alternative to...

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer )

Also on site :

• This Common Over-the-Counter Medication May Harm Brain Health, Doctors Say—Do You Take It?
• In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook
• Explosion at fireworks factory in China kills 9, state media says